02-18 AVEO Oncology Announces Completion of the First Interim Analysis in the Global Phase 3 FIERCE-HN Study CI
01-14 AVEO Oncology Announces First Patient Dosed in Front-Line AML Combination Study of Ficlatuzumab CI
25-02-18 AVEO Oncology Presents Two Posters for Tivozanib at the 2025 ASCO GU Meeting CI
24-09-16 AVEO Pharmaceuticals, Inc. Presents TiNivo-2 Results and TIVO-3 Exploratory Post Immunotherapy Survival Analysis at ESMO 2024 CI
24-07-18 Aveo Oncology Announces Phase 3 Renal Cell Carcinoma Clinical Trial (TiNivo-2) Results CI
24-06-13 LG Chem Company and AVEO Oncology Announce LG Chem's First Proprietary Anti-Cancer Compound Enters Phase 1 Clinical Study, Dosing Initiated in the U.S CI
24-03-25 AVEO Pharmaceuticals, Inc. Announces Executive Changes CI
24-02-06 Aveo Oncology Announces Publication of Long-Term Survival in Patients with Relapsed/Refractory Advanced Renal Cell Carcinoma Treated with Tivozanib: Analysis of the Phase Iii Tivo-3 Trial in the Oncologist CI
24-01-16 AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) CI
23-06-27 AVEO Oncology Announces Completion of Enrollment in Pivotal Phase 3 TiNivo-2 Study of FOTIVDA(R) in Combination with OPDIVO(R) in Advanced Renal Cell Carcinoma CI
23-01-20 South Korean Stocks Climb on Demand Recovery Hopes from China; LG Chem Stocks Add 1% MT
23-01-20 AVEO Completes Acquisition by LG Chem MT
23-01-19 LG Chem Acquires US Biopharma Firm AVEO Pharmaceuticals MT
Manager TitleAgeSince
Chief Executive Officer 60 2015-01-05
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer - 2022-07-31
Director TitleAgeSince
Director/Board Member 60 -
Director/Board Member - -
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap.
23-01-18Issuer sale

Chief Operating Officer

197,702 0.5687%
23-01-18Issuer sale

Chief Executive Officer

1,713,123 4.9280%
23-01-18Issuer sale

Director

47,500 0.1366%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+0.20% - - 521M
-0.53%+1.67%+19.19%-20.47% 63.09B
-0.12%+2.64%+51.84%+216.65% 55.61B
+0.07%+38.60%+38.60%+38.60% 41.64B
-2.36%-1.25%-52.13%-58.98% 38.98B
+1.19%+2.74%+58.64%-29.02% 29.82B
-1.11%-6.58%+122.45%-49.58% 23.71B
-0.86%+9.48%+59.19%+72.19% 21.48B
-1.25%-0.27%-4.39%+142.42% 16.87B
-1.91%+3.64%+65.83%+121.63% 16.74B
Average -0.69%+2.98%+39.91%+48.16% 34.22B
Weighted average by Cap. -0.62%+2.91%+34.48%+45.51%
Logo AVEO Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company. The Company is focused on delivering medicines for patients with cancer. The Company's commercial product include FOTIVDA (tivozanib), which is an oral, vascular endothelial growth factor receptor (VEGFR) and tyrosine kinase inhibitor (TKI). The Company markets FOTIVDA (tivozanib) in the United States for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. It also develops FOTIVDA in immuno-oncology combinations in refractory RCC and other indications and has several other investigational programs in clinical development. The Company's pipeline of product candidates includes ficlatuzumab, AV-380, AV-203 and AV-353. Its ficlatuzumab is a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor (HGF).
Employees
114
  1. Stock Market
  2. Stocks
  3. AVEO Stock